Full-Time

Operational Excellence Leader

Posted on 11/15/2025

Bachem

Bachem

1,001-5,000 employees

Develops and manufactures peptides and oligonucleotides

Compensation Overview

$157.3k - $200k/yr

+ Annual Performance Bonus + 401(k) Match + Medical/Dental/Vision coverage

Oceanside, CA, USA

In Person

Must be able to travel to different office locations or facilities as needed.

Category
Operations & Logistics (1)
Requirements
  • Bachelor's degree in engineering, chemistry, manufacturing, operations management, or related field
  • Master's Degree or MBA preferred
  • 10+ years of experience in operational excellence, process improvement, or manufacturing management, preferably in the chemical/pharmaceutical manufacturing industry
  • Proven track record of leading large-scale OpEx transformation projects with measurable success
  • Strong expertise in Lean Six Sigma, and other continuous improvement methodologies
  • Green or Black Belt required (Black Belt preferred)
  • Exceptional leadership, communication, and interpersonal skills with the ability to influence and motivate others at all levels of the organization
  • Proven ability in developing and mentoring talent (critical for MBB as they need to mentor belts through their certification and projects)
  • Demonstrated ability to develop and implement strategic initiatives that align with business goals
  • Experience in managing change in a complex and fast-paced environment
  • Strong analytical and problem-solving skills, with a data-driven approach to decision-making
  • Knowledge of industry regulations, safety standards, and sustainability practices
  • Ability to travel to different office locations or facilities as needed
Responsibilities
  • Safety & Quality: ensure consistency and prioritization of safety and quality behaviors through shopfloor processes and metrics
  • Strategic Leadership: develop and implement a comprehensive Operational Excellence strategy that aligns with the company’s overall business objectives; Identify opportunities for improvement across the entire value chain, from procurement to production to delivery
  • Cross-Functional Collaboration: collaborate with department heads, site managers, and other key stakeholders to ensure alignment of operational excellence initiatives with business goals; Act as a change agent to promote a culture of continuous improvement across the organization
  • Team Development: build and mentor a team of passionate improvement ambassadors (green/black belts) across functions and sites and support the development of their skills and the execution of improvement projects
  • Performance Management: establish key performance indicators (KPIs) and metrics to measure the effectiveness of Operational Excellence initiatives and monitor overall performance of the end-to-end operations processes across functions; monitor progress and adjust strategies as needed to ensure that targets are met
  • Cost Optimization: ensure and manage a list of continuous improvement opportunities balanced between shopfloor improvement, production process improvement and business process improvement; Quantify impact on operational costs, increased efficiency, and improved profitability. Follow up on delivery of proposed improvement potential
  • Sustainability & Compliance: ensure that all transformation initiatives are sustainable and comply with industry regulations and safety standards; Promote a culture of safety and environmental responsibility
  • Change Management: develop and execute change management plans to ensure smooth implementation of new processes and systems; Engage employees at all levels to gain buy-in and support for transformation initiatives
  • Innovation: stay abreast of industry trends, emerging technologies, and best practices in operational excellence; Introduce innovative solutions that drive continuous improvement and operational efficiency

Bachem provides development and manufacturing of peptides and oligonucleotides for research, clinical development, and commercial products. Its offerings include custom synthesis and scale-up production, analytical testing, and related services across the drug development spectrum. Customers work with Bachem by specifying desired sequences and specifications, after which Bachem designs, synthesizes, and quality-controls the peptides or oligonucleotides and delivers them in appropriate scales and formats. The company differentiates itself through more than five decades of experience, a global footprint with sites in Europe, the US, and Asia, and an integrated set of services spanning discovery support to commercial manufacturing. Its goal is to help pharmaceutical and biotechnology companies advance peptide- and oligonucleotide-based therapies by providing reliable, scalable, and well-supported manufacturing and development capabilities.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Bubendorf, Switzerland

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • Oligonucleotide market expansion via TIRmed Pharma collaboration for atopic dermatitis.
  • CHF 500 million credit facility enables capacity expansion toward CHF 1B revenue target.
  • New CEO Anne-Kathrin Stoller brings Americas operational expertise and commercial focus.

What critics are saying

  • CEO transition disrupts execution of strategic growth initiatives through 2026.
  • Elevated debt servicing costs from syndicated facility erode 30% EBITDA margin target.
  • Chinese competitors scale oligonucleotide production at 40% lower costs via subsidies.

What makes Bachem unique

  • Leading peptide and oligonucleotide CDMO with 50+ years manufacturing expertise.
  • Integrated GMP capabilities for clinical-stage oligonucleotide therapeutics development.
  • Global footprint across Switzerland, US, and Europe with established pharma relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Company News

Nordic Life Science
Nov 18th, 2025
TIRmed Pharma collaborates with Bachem

TIRmed Pharma collaborates with Bachem. The collaboration includes process development and manufacturing of TIR-01, the active substance in TIRmed's treatment for atopic dermatitis (eczema), and marks an important step towards future clinical trials. As part of its preclinical program, TIRmed Pharma is collaborating with Bachem to establish high-quality production processes for TIR-01, an oligonucleotide-based compound, they describe in a press release. With its expertise in oligonucleotide production, Bachem provides critical expertise for GMP development, ensuring stability, consistency and regulatory compliance for upcoming clinical studies according to the company. "The collaboration with Bachem is an important milestone in the work of taking our drug candidate further towards the clinic," says Leo Holmgren, CEO of TIRmed Pharma. "It gives us access to world-leading manufacturing expertise and strengthens the foundation for being able to offer patients a longer-term treatment alternative," he adds. Learn more about the science behind TIRmed Pharma and its connections to this year's Nobel Prize in Medicine in our latest issue of the magazine - out now!

CHEManager
Oct 31st, 2025
Anne-Kathrin Stoller Becomes New CEO at Bachem

Anne-Kathrin Stoller becomes new CEO at Bachem. Bachem announced today that the Board of Directors has appointed Anne-Kathrin Stoller, the former Head of Bachem Americas and previously the company's CMO for many years, as the new CEO effective january 1, 2026. She succeeds Thomas Meier, who has decided to take on a new challenge outside the company after more than thirty years at Bachem and almost six years as CEO. "Thomas Meier has contributed significantly to Bachem's continued success. Together with his team, he has achieved a capital-efficient and profitable growth. At the same time, Bachem's position as an innovative and reliable partner to the pharmaceutical industry has been further strengthened. We would like to express our sincere thanks to Thomas for his many years of service, his leadership and extraordinary contribution to Bachem," says Kuno Sommer, Chairman of the Board of Directors of Bachem. He continues: "I am very pleased that we have been able to appoint Anne-Kathrin Stoller, an experienced and competent successor from within our own ranks, as the new CEO. Anne-Kathrin has an excellent combination of expertise, leadership skills, and customer focus and, together with her colleagues in the Executive Committee, will continue Bachem's successful course." Thomas Meier, CEO, Bachem, added: "Bachem is a great company and has developed into a leading global, innovation-driven developer and manufacturer of peptides and oligonucleotides in recent years. I have had the privilege of helping to shape and accompany this development in various roles over the past three decades, and I am very grateful for the many enriching experiences I have had at work and the formative encounters with people. Above all, I would like to thank Bachem's employees and customers, as well as my colleagues in the Executive Committee and on the Board of Directors, for their active support and excellent cooperation." Anne-Kathrin Stoller, current Head of Bachem Americas and future CEO, Bachem, commented: "I am delighted to have earned the trust of the Board of Directors and will do everything in my power, together with the members of the Executive Committee and all Bachem employees, to continue our company's impressive success story. Under the leadership of Thomas Meier, Bachem has set the course for the future. I would like to thank him for his collegial support over the past years and everyone at Bachem who works hard every day to ensure that we make an important contribution to human health." Anne-Kathrin Stoller has worked for Bachem since 2006. After holding various management positions, including Head of Business Development & Sales Europe, Chief Marketing Officer and member of the Group Executive Board, she took on the role of Chief Operating Officer Americas in 2022 and is responsible for the company's US business. Anne-Kathrin Stoller studied chemistry in Hanover and Cambridge (UK) and holds a doctorate in bioorganic chemistry from the University of Basel.

Stock Titan
Aug 20th, 2025
Bachem Expands Corporate Executive Committee to Include Chief Operations Officer Role

Bachem (OTC:BCHMY) has announced the appointment of Hans Van Hees as Chief Operations Officer (COO), effective September 1, 2025.

Stock Titan
Jul 24th, 2025
Bachem Shows Strong Growth in the First Half of 2025

Looking ahead, Bachem aims to achieve annual sales exceeding CHF 1 billion and an EBITDA margin over 30% by 2026, supported by significant investments including the new Building K facility and planned expansion in Sisslerfeld.

PharmiWeb.com
Nov 27th, 2024
Green Manufacturing In Pharma: Sustainable Oligonucleotide Production On An Industrial Scale

Oligonucleotides are at the forefront of modern medicine, and have emerged as powerful tools in treating diseases in recent years. Oligonucleotides – short DNA or RNA molecules that host a range of applications in genetic testing, research, and forensics – have seen a marked growth in significance as therapeutics. As their clinical application widens, methods of production must be robust to ensure demand is met. Demand for oligonucleotides in medicines is steadily increasing, with pressing need for an eco-friendly manufacturing process which satisfies green manufacturing standards without compromising yield or process efficiency. Thus, the responsibility lies with manufacturers to ensure end users receive their medications, while striving for sustainable production methods

INACTIVE